Henlius Biotech's Breast Cancer Drug Included in China's Reimbursement Drug List
MT Newswires Live
Yesterday
Shanghai Henlius Biotech (HKG:2696) said its breast cander drug, FUTUONING, has been included in China's National Reimbursement Drug List, a Sunday Hong Kong bourse filing said.
Shares of the drugmaker were down over 2% in Monday afternoon trading.
The inclusion is for the indication of drug in combination with Fulvestrant for the treatment of adult patients with breast cancer who have experienced disease progression after prior endocrine therapy.
The new edition of the list will become effective on Jan. 1, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.